We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





Practical Approaches to Measuring and Interpreting Alzheimer’s Disease Biomarkers

By Jen A. Miller (ADLM)
Posted on 29 Jun 2025

Amyloid-targeting therapies are potential game changers for treating Alzheimer’s disease (AD), which affects over 7 million people in the U. More...

S., according to the Alzheimer’s Association. Two such treatments, the monoclonal antibodies lecanemab and donanemab, were approved by the Food and Drug Administration in 2023 and 2024, respectively. They work by identifying and removing amyloid plaques from the brain, which slows and delays cognitive decline.

These breakthrough treatments have also brought more attention to testing for AD, which can help clinicians to determine which patients with mild-stage disease are good candidates for the medications. “These two new drugs have brought out interest in the Alzheimer’s disease biomarker field in clinical practice,” said Danting Liu, PhD, a clinical chemistry fellow in the clinical immunoassay laboratory in the department of laboratory medicine and pathology at the Mayo Clinic in Rochester, Minnesota. At a roundtable session at ADLM 2025 (formerly the AACC Annual Scientific Meeting & Clinical Lab Expo), Liu will discuss the resulting opportunities and challenges for the clinical lab and clarify confusion among clinicians about which tests to use.

Typically, AD biomarkers can be measured in two ways: through cerebrospinal fluid (CSF) for Aß42/40 ratio and p-tau181/Aß42 ratio; and through blood for p-tau217 and Aß42/40. The blood-based tests, which measure biomarkers in plasma, are less invasive and easier to collect, Liu said. This often makes them more attractive to clinicians who want to pick the least painful test for their patients.

But blood-based tests are not as accurate as CSF-based ones because plasma contains lower concentrations of the biomarkers than CSF. That doesn’t mean blood-based tests are worthless, but rather that clinicians must take multiple factors into consideration when choosing an assay. “This session is timely in that it helps clinics and lab professionals know the strengths and limitations of these tests,” Liu said.

She will guide attendees through case studies and interactive discussions, where they will learn about assay selection, handling biomarker variability, and enhancing patient care through the careful applications of AD biomarkers.

Just as selecting an assay is not cut and dried, neither is interpreting results. For example, the CSF test isn’t an individual assay but instead a panel, where results are used to calculate ratios. “Sometimes a ratio might be positive, but other markers may be in the normal range,” Liu said.

The session will use real patient data to show how the tests work and pinpoint where confusion over results often comes in. “We’re going to bring some cases to show different patterns and how to interpret those in different conditions,” Liu added. She’ll give attendees actionable advice on how to “interpret the results when they are discordant or they are in rare patterns.”

Liu anticipates that discussions around the use of these tests and their interpretation will become more critical as demand for amyloid-targeting therapies grows and AD becomes more prevalent due to an aging population. According to the Alzheimer’s Association, AD already costs an estimated $384 billion in health and long-term care expenses. The monoclonal antibody treatments are pricey as well. For example, Leqembi, the brand name for lecanemab, costs $26,500 per year, and CMS expects to spend $3.5 billion on it in 2025, according to a report from Stat News.

“I have encountered many questions from clinicians about when to offer these tests and how to choose between them,” Liu said. “In real practice, the interpretation of those biomarkers isn’t always straightforward, so I thought this would be a great opportunity to share our knowledge and experience,” she added.


New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Serological Pipet Controller
PIPETBOY GENIUS
New
8-Channel Pipette
SAPPHIRE 20–300 µL
New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: A diagnostic test can distinguish patients with head and neck squamous cell carcinoma who can be cured with surgery alone (Photo courtesy of University of Turku)

Novel Diagnostic Tool to Revolutionize Treatment Guidance of Head and Neck Cancer

Head and neck squamous cell carcinoma (HNSCC) is a solid tumor type commonly treated with surgery. However, there has been no clinically available method to determine which patients can be cured with surgery... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more

Microbiology

view channel
Image: The groundbreaking salmonella antimicrobial resistance prediction platform has demonstrated 95% accuracy (Photo courtesy of Yujie You et al., DOI: 10.1016/j.eng.2025.01.013)

New Platform Leverages AI and Quantum Computing to Predict Salmonella Antimicrobial Resistance

Antimicrobial-resistant Salmonella strains are a growing public health concern due to the overuse of antimicrobials and the rise of genetic mutations. Accurate prediction of resistance is crucial for effective... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.